ReviewMediators of inflammation2016
MicroRNA-Regulated Proinflammatory Cytokines in Sarcopenia.
Review in Mediators of inflammation, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 40 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
40 citing papers in PubMed, 1 synthesis or guideline pooled it, 85 citations in OpenAlex.
- MicroRNAs in Sarcopenia: A Systematic Review.Frontiers in medicine · 2020Pooled it
- Protective Effects ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Ultrasound Elastography for the Assessment of Sarcopenia.Journal of clinical medicine · 2026Review
- Correlation between oxidative stress and inflammation with metabolomics profile in skeletal muscle of ageing animal model and its modulation by tocotrienol-rich fraction.British journal of biomedical science · 2026Article
- Immunosenescence and the Geriatric Giants: Molecular Insights into Aging and Healthspan.Medical sciences (Basel, Switzerland) · 2025Review
- Article
- Inflammation centered muscle signature of sarcopenia from postmenopausal women in Shanghai China.Frontiers in cell and developmental biology · 2025Article
- Sarcopenia and Associated Factors in Adults Aged 40 and Above: A Study Conducted in Primary Healthcare.Cureus · 2024Article
- Chronic pain in the elderly: Exploring cellular and molecular mechanisms and therapeutic perspectives.Frontiers in aging · 2024Review
- Effects of Horse Meat Hydrolysate on Oxidative Stress, Proinflammatory Cytokines, and the Ubiquitin-Proteasomal System of C2C12 Cells.Food science of animal resources · 2024Article
- Milk fat miRNome changes in response to LPS challenge in Holstein cows.Veterinary research · 2023Article
- The Impact of Complex Rehabilitation Treatment on Sarcopenia-Pathology with an Endocrine Morphological Substrate and Musculoskeletal Implications.Medicina (Kaunas, Lithuania) · 2023Article
- Prevalence of sarcopenia among patients with hepatocellular carcinoma: A systematic review and meta‑analysis.Oncology letters · 2023Article
- Identification of novel pathways and immune profiles related to sarcopenia.Frontiers in medicine · 2023Article
- Effects of functional training with blood occlusion on the irisin, follistatin, and myostatin myokines in elderly men.European review of aging and physical activity : official journal of the European Group for Research into Elderly and Physical Activity · 2022Article
- Associations between sarcopenia with asthmatic prevalence, lung function and comorbidity.BMC geriatrics · 2022Article
- Differential effects of calorie restriction and rapamycin on age-related molecular and functional changes in skeletal muscle.Experimental gerontology · 2022Article
- Development and validation of a novel diagnostic model for musculoskeletal aging (sarcopenia) based on cuproptosis-related genes associated with immunity.American journal of translational research · 2022Article
- Non-coding RNA basis of muscle atrophy.Molecular therapy. Nucleic acids · 2021Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sarcopenia has been defined as the aging-related disease with the declined mass, strength, and function of skeletal muscle, which is the major cause of frailty and falls in elders. The activation of inflammatory signal pathways due to diseases and aging is suggested to reveal the critical impact on sarcopenia. Several proinflammatory cytokines, especially interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α), play crucial roles in modulation of inflammatory signaling pathway during the aging-related loss of skeletal muscle. MicroRNAs (miRNAs) have emerged as the important regulators for the mass and functional maintenance of skeletal muscle through regulating gene expression of proinflammatory cytokines. In this paper, we have systematically discussed regulatory mechanisms of miRNAs for the expression and secretion of inflammatory cytokines during sarcopenia, which will provide some novel targets and therapeutic strategies for controlling aging-related atrophy of skeletal muscle and corresponding chronic inflammatory diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.